New Zealand

New Zealand

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.9 (0.78 - 1.01) 2019 Modelled IHME
0.91 (0.80 - 1.02) 2018 Modelled IHME
0.91 (0.80 - 1.03) 2017 Modelled IHME
0.91 (0.80 - 1.01) 2016 Modelled IHME
0.9 (0.79 - 1.01) 2015 Modelled IHME
0.91 (0.80 - 1.01) 2014 Modelled IHME
0.92 (0.81 - 1.03) 2013 Modelled IHME
0.94 (0.82 - 1.05) 2012 Modelled IHME
0.95 (0.83 - 1.07) 2011 Modelled IHME
0.97 (0.84 - 1.09) 2010 Modelled IHME
0.98 (0.86 - 1.11) 2009 Modelled IHME
0.99 (0.87 - 1.12) 2008 Modelled IHME
1.01 (0.88 - 1.13) 2007 Modelled IHME
1.02 (0.89 - 1.16) 2006 Modelled IHME
1.03 (0.90 - 1.17) 2005 Modelled IHME
1.05 (0.92 - 1.19) 2004 Modelled IHME
1.06 (0.93 - 1.20) 2003 Modelled IHME
1.08 (0.95 - 1.21) 2002 Modelled IHME
1.09 (0.96 - 1.23) 2001 Modelled IHME
1.11 (0.97 - 1.25) 2000 Modelled IHME
1.13 (0.98 - 1.27) 1999 Modelled IHME
1.15 (1 - 1.29) 1998 Modelled IHME
1.17 (1.01 - 1.31) 1997 Modelled IHME
1.18 (1.03 - 1.34) 1996 Modelled IHME
1.2 (1.04 - 1.37) 1995 Modelled IHME
1.22 (1.06 - 1.39) 1994 Modelled IHME
1.24 (1.07 - 1.41) 1993 Modelled IHME
1.26 (1.09 - 1.43) 1992 Modelled IHME
1.27 (1.10 - 1.47) 1991 Modelled IHME
1.29 (1.11 - 1.50) 1990 Modelled IHME
3.13 (2.51 - 3.89) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.07 (0.05 - 0.08) 2019 Modelled IHME
0.07 (0.05 - 0.09) 2018 Modelled IHME
0.07 (0.05 - 0.09) 2017 Modelled IHME
0.07 (0.05 - 0.09) 2016 Modelled IHME
0.07 (0.05 - 0.09) 2015 Modelled IHME
0.07 (0.06 - 0.09) 2014 Modelled IHME
0.07 (0.06 - 0.09) 2013 Modelled IHME
0.07 (0.06 - 0.09) 2012 Modelled IHME
0.07 (0.06 - 0.09) 2011 Modelled IHME
0.08 (0.06 - 0.10) 2010 Modelled IHME
0.08 (0.06 - 0.10) 2009 Modelled IHME
0.09 (0.07 - 0.11) 2008 Modelled IHME
0.09 (0.07 - 0.12) 2007 Modelled IHME
0.1 (0.08 - 0.13) 2006 Modelled IHME
0.1 (0.08 - 0.13) 2005 Modelled IHME
0.11 (0.08 - 0.14) 2004 Modelled IHME
0.11 (0.09 - 0.14) 2003 Modelled IHME
0.12 (0.09 - 0.15) 2002 Modelled IHME
0.12 (0.09 - 0.15) 2001 Modelled IHME
0.12 (0.10 - 0.16) 2000 Modelled IHME
0.13 (0.10 - 0.16) 1999 Modelled IHME
0.13 (0.10 - 0.17) 1998 Modelled IHME
0.14 (0.11 - 0.18) 1997 Modelled IHME
0.15 (0.11 - 0.19) 1996 Modelled IHME
0.15 (0.12 - 0.20) 1995 Modelled IHME
0.17 (0.13 - 0.22) 1994 Modelled IHME
0.18 (0.14 - 0.23) 1993 Modelled IHME
0.2 (0.16 - 0.26) 1992 Modelled IHME
0.22 (0.17 - 0.28) 1991 Modelled IHME
0.25 (0.19 - 0.31) 1990 Modelled IHME
1.2 (0.83 - 1.70) 2015 Modelled WHO
0.2 2009 Survey/reported WHO WPRO, Woodring J et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
15 (13 - 18) 2019 Modelled IHME
15 (12 - 18) 2018 Modelled IHME
15 (13 - 18) 2017 Modelled IHME
15 (13 - 18) 2016 Modelled IHME
15 (13 - 18) 2015 Modelled IHME
15 (13 - 18) 2014 Modelled IHME
15 (13 - 18) 2013 Modelled IHME
16 (13 - 19) 2012 Modelled IHME
16 (13 - 19) 2011 Modelled IHME
16 (13 - 19) 2010 Modelled IHME
16 (13 - 19) 2009 Modelled IHME
16 (13 - 19) 2008 Modelled IHME
16 (13 - 19) 2007 Modelled IHME
16 (13 - 19) 2006 Modelled IHME
16 (13 - 19) 2005 Modelled IHME
16 (13 - 19) 2004 Modelled IHME
16 (13 - 19) 2003 Modelled IHME
16 (13 - 19) 2002 Modelled IHME
16 (13 - 19) 2001 Modelled IHME
16 (14 - 19) 2000 Modelled IHME
16 (14 - 19) 1999 Modelled IHME
16 (14 - 19) 1998 Modelled IHME
16 (14 - 19) 1997 Modelled IHME
16 (13 - 19) 1996 Modelled IHME
16 (13 - 19) 1995 Modelled IHME
16 (14 - 19) 1994 Modelled IHME
16 (14 - 20) 1993 Modelled IHME
17 (14 - 20) 1992 Modelled IHME
17 (14 - 20) 1991 Modelled IHME
17 (14 - 21) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
93 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
92 2016 Survey/reported WHO/UNICEF
92 2015 Survey/reported WHO/UNICEF
93 2014 Survey/reported WHO/UNICEF
93 2013 Survey/reported WHO/UNICEF
93 2012 Survey/reported WHO/UNICEF
95 2011 Survey/reported WHO/UNICEF
90 2010 Survey/reported WHO/UNICEF
93 2009 Survey/reported WHO/UNICEF
90 2008 Survey/reported WHO/UNICEF
88 2007 Survey/reported WHO/UNICEF
87 2006 Survey/reported WHO/UNICEF
87 2005 Survey/reported WHO/UNICEF
88 2004 Survey/reported WHO/UNICEF
89 2003 Survey/reported WHO/UNICEF
89 2002 Survey/reported WHO/UNICEF
90 2001 Survey/reported WHO/UNICEF
90 2000 Survey/reported WHO/UNICEF
89 1999 Survey/reported WHO/UNICEF
87 1998 Survey/reported WHO/UNICEF
99 1997 Survey/reported WHO/UNICEF
94 1996 Survey/reported WHO/UNICEF
88 1995 Survey/reported WHO/UNICEF
81 1994 Survey/reported WHO/UNICEF
74 1993 Survey/reported WHO/UNICEF
67 1992 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
124 (93 - 185) 2016 Survey/reported Noller G and Leafe K, 2016; New Zealdn Ministry of Health, 2014

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
48.1 (44.30 - 51.80) 2013 Survey/reported Noller G and Leafe K, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.78 (0.63 - 0.95) 2019 Modelled IHME
0.78 (0.63 - 0.94) 2018 Modelled IHME
0.77 (0.62 - 0.94) 2017 Modelled IHME
0.76 (0.61 - 0.93) 2016 Modelled IHME
0.75 (0.60 - 0.92) 2015 Modelled IHME
0.75 (0.61 - 0.92) 2014 Modelled IHME
0.75 (0.61 - 0.92) 2013 Modelled IHME
0.75 (0.61 - 0.92) 2012 Modelled IHME
0.75 (0.61 - 0.91) 2011 Modelled IHME
0.75 (0.60 - 0.92) 2010 Modelled IHME
0.75 (0.61 - 0.91) 2009 Modelled IHME
0.75 (0.61 - 0.91) 2008 Modelled IHME
0.74 (0.61 - 0.91) 2007 Modelled IHME
0.74 (0.60 - 0.91) 2006 Modelled IHME
0.74 (0.60 - 0.91) 2005 Modelled IHME
0.74 (0.60 - 0.90) 2004 Modelled IHME
0.74 (0.60 - 0.90) 2003 Modelled IHME
0.73 (0.59 - 0.90) 2002 Modelled IHME
0.73 (0.59 - 0.89) 2001 Modelled IHME
0.73 (0.59 - 0.90) 2000 Modelled IHME
0.73 (0.59 - 0.90) 1999 Modelled IHME
0.74 (0.59 - 0.90) 1998 Modelled IHME
0.74 (0.60 - 0.91) 1997 Modelled IHME
0.74 (0.60 - 0.91) 1996 Modelled IHME
0.75 (0.60 - 0.92) 1995 Modelled IHME
0.75 (0.60 - 0.91) 1994 Modelled IHME
0.75 (0.60 - 0.92) 1993 Modelled IHME
0.75 (0.60 - 0.92) 1992 Modelled IHME
0.74 (0.60 - 0.92) 1991 Modelled IHME
0.74 (0.60 - 0.92) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.9 (0.80 - 2.20) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
71.9 (63.20 - 80.60) 2015 Modelled

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
31 (28 - 35) 2019 Modelled IHME
32 (28 - 36) 2018 Modelled IHME
32 (28 - 36) 2017 Modelled IHME
31 (28 - 35) 2016 Modelled IHME
31 (27 - 34) 2015 Modelled IHME
30 (27 - 34) 2014 Modelled IHME
30 (26 - 34) 2013 Modelled IHME
30 (26 - 34) 2012 Modelled IHME
30 (26 - 34) 2011 Modelled IHME
30 (26 - 33) 2010 Modelled IHME
30 (26 - 33) 2009 Modelled IHME
30 (26 - 33) 2008 Modelled IHME
30 (26 - 33) 2007 Modelled IHME
30 (26 - 33) 2006 Modelled IHME
30 (26 - 33) 2005 Modelled IHME
30 (26 - 33) 2004 Modelled IHME
30 (26 - 33) 2003 Modelled IHME
30 (26 - 34) 2002 Modelled IHME
30 (26 - 34) 2001 Modelled IHME
30 (26 - 34) 2000 Modelled IHME
30 (26 - 33) 1999 Modelled IHME
29 (26 - 33) 1998 Modelled IHME
29 (26 - 33) 1997 Modelled IHME
29 (26 - 33) 1996 Modelled IHME
29 (25 - 33) 1995 Modelled IHME
29 (25 - 32) 1994 Modelled IHME
28 (25 - 32) 1993 Modelled IHME
28 (25 - 32) 1992 Modelled IHME
28 (25 - 32) 1991 Modelled IHME
28 (25 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (93 - 185) 2016 Survey/reported Noller G and Leafe K, 2016; New Zealdn Ministry of Health, 2014

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
48.1 (44.30 - 51.80) 2013 Survey/reported Noller G and Leafe K, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.9 (%)
2019
(0.78 - 1.01(%))
IHME
HCV (RNA/cAg+)
0.78 (%)
2019
(0.63 - 0.95(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
88
2019
(77 - 99)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
211
2019
(188 - 234)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.07 (%)
2019, latest modelled
(0.05 - 0.08(%))
IHME

Prevalence PWID

HCV
71.90 (%)
2015, latest modelled
(63.20 - 80.60(%))

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
124
2016
(93 - 185)
Noller G and Leafe K, 2016; New Zealdn Ministry of Health, 2014
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Partners